Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is a Healthcare company (Biotechnology) with a market capitalization of $1.8B. The Maz Rating grades it against the other companies in its sector.
Agios Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $30.15, Agios Pharmaceuticals, Inc. trades at 13.0x sales and 1.9x book value. Over the last twelve months it generated about $139M of revenue and a net loss of $373M. It runs a gross margin of 91.9%, an operating margin of -297.7% and a net margin of -264.8%. It shows return on equity of -34.6%, return on invested capital of -41.6% and a free cash flow yield of -18.6%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 9.69. Over the past 52 weeks the share price ranged from $22.24 to $46.00, with a beta of 0.62.
Agios Pharmaceuticals, Inc. does not currently pay a dividend.
29 Wall Street analyst ratings cover the stock: 22 Buy and 7 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.